Stemline Therapeutics, Inc.
Stemline Therapeutics is focused on the development & commercialization of novel oncology therapeutics. In December '18, the FDA approved ELZONRIS (tagraxofusp-erzs; SL-401), a targeted therapy directed to CD123, for the treatment of adult & pediatric patients, two years or older, with (BPDCN). A marketing authorization application (MAA) is under review by the EMA. ELZONRIS is being evaluated in additional indications including CMML, MF & AML. Pipeline candidates include SL-701 (immunotherapeutic), SL-801 (XPO1 inhibitor), SL-901 (novel kinase inhibitor) & SL-1001 (novel RET kinase inhibitor).